Watch our short animated explainer video to understand our technology, below.
Play Video
CLINICAL DEVELOPMENT
Clinical Trials at Jabez Biosciences
At Jabez, we are developing a smarter model for cancer therapy. Our therapeutics are strategically deployed to improve patient outcomes without adding complexity.
Now Enrolling:
JBZ-001: Phase 1 Clinical Trial
Cancer Types: Advanced Solid Tumors & Non-Hodgkin’s Lymphoma
Primary Objectives: Our Phase 1 trial is evaluating the safety, tolerability, and pharmacokinetics/ pharmacodynamics of JBZ-001 in patients with specific advanced cancers.
Locations: We are partnering with leading cancer institutes across the United States
Participating Clinics:
Clinical Trials Identifier: NCT############
ELIGIBILIY
Is This Trial Right For You?
We’re looking for participants who meet specific criteria to ensure both patient safety and meaningful scientific results. While your healthcare provider can help determine your eligibility, here’s a general overview:
Basic Criteria
- Adults (18+) with confirmed advanced solid tumors or non-Hodgkin lymphoma
- Previous treatment with standard therapies without adequate response
- Adequate organ function and performance status
- No active CNS metastases requiring treatment
Full criteria are available through participating sites. Your oncologist can help determine if this trial aligns with your specific situation.
Interested in joining this trial?
If you are interested in participating in this study, call The JamesLine at 800-293-5066 to make an appointment with the principal investigator listed or ask your doctor if you are eligible for this study.
JBZ-001:
Our Lead Compound
JBZ-001 is an oral DHODH inhibitor currently in a Phase 1 clinical trial for advanced solid tumors and non-Hodgkin lymphoma.
It brilliantly exemplifies our 3-C model:
- Convenient: Well-tolerated, oral small molecule
- Cost-Effective: Leverages Nobel Prize-winning, scalable chemistry
- Cooperative: Displays potent synergy with well-established treatment regimens.
Jabez Biosciences is developing a smarter model for cancer therapy.
Social Media
Jabez Biosciences. 2025. All Rights Reserved. Website made by Flyte Bio.
